Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
CPRX is in the long-term up 355% in 4 years.
Description: Catalyst Pharmaceutical Partners, Inc. operates as development-stage specialty pharmaceutical company. The company focuses on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases and disorders. Its principal product candidate is Firdapse, a proprietary form of amifampridine phosphate, which is in Phase III clinical trial for the treatment of Lambert-Eaton Myasthenic Syndrome. The company also develops CPP-115, a vigabatrin analog to treat infantile spasms and epilepsy, as well as other neurological conditions associated with reduced GABAergic signaling, such as post-traumatic stress disorder and Tourette syndrome. Catalyst Pharmaceutical Partners, Inc. has strategic collaboration agreement with BioMarin. The company was founded in 2002 and is based in Coral Gables, Florida.
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||Sales Growth - Q/Q||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-22.5%||ROE||-25.68%||ROI|
|Current Ratio||12.99||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.09|
|Gross Margin||Operating Margin||Net Profit Margin||Dividend Payout Ratio|
|Cash From Financing Activities||36.06 M||Cash From Investing Activities||-40 K||Cash From Operating Activities||-3.79 M||Gross Profit|
|Net Profit||-5.41 M||Operating Profit||-4.29 M||Total Assets||76.05 M||Total Current Assets||75.97 M|
|Total Current Liabilities||5.85 M||Total Debt||Total Liabilities||9.43 M||Total Revenue|
|High 52 week||3.84||Low 52 week||1.92||Last close||2.88||Last change||-1.03%|
|RSI||77.42||Average true range||0.13||Beta||0.6||Volume||310.27 K|
|Simple moving average 20 days||11.78%||Simple moving average 50 days||18.31%||Simple moving average 200 days||-3.21%|
|Performance Week||3.97%||Performance Month||16.13%||Performance Quart||3.23%||Performance Half||-3.03%|
|Performance Year||-8.57%||Performance Year-to-date||50%||Volatility daily||3.02%||Volatility weekly||6.74%|
|Volatility monthly||13.82%||Volatility yearly||47.87%||Relative Volume||298.06%||Average Volume||1.79 M|
|New High||New Low|
2019-06-12 09:46:42 | UPDATE 2-Catalyst Pharma sues FDA over approval of cheaper rival drug
2019-06-12 09:30:01 | Catalyst CPRX Up 14.1% Since Last Earnings Report: Can It Continue?
2019-06-12 08:47:00 | Catalyst Pharmaceuticals Files Federal Lawsuit Against U.S. Food and Drug Administration
2019-06-04 08:03:00 | Catalyst Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference
2019-05-30 08:03:00 | Catalyst Pharmaceuticals Announces Expansion of Firdapse License to Include Japan
2019-05-28 14:33:05 | Catalyst Pharmaceuticals settles patent dispute with Northwestern University
2019-05-22 15:47:07 | Catalyst Pharma CPRX Rides on Successful Launch of Firdapse
2019-05-22 12:57:50 | Edited Transcript of CPRX earnings conference call or presentation 13-May-19 12:30pm GMT
2019-05-18 07:15:48 | 5 Biotech Stocks to Watch in the Second Half of 2019
2019-05-16 11:00:00 | Are These 2 Beaten-Down Biotech Stocks Worth the Risk?
2019-05-14 14:36:06 | Catalyst CPRX Q1 Loss Narrows, Firdapse Off to a Good Start
2019-05-14 08:44:12 | Implied Volatility Surging for Catalyst Pharmaceuticals CPRX Stock Options
2019-05-13 14:00:00 | Catalyst Pharmaceuticals Posts Strong Q1 Sales for Firdapse
2019-05-13 13:10:00 | Why Catalyst Pharmaceuticals Briefly Spiked Today
2019-05-13 12:23:14 | Catalyst Pharmaceuticals Inc CPRX Q1 2019 Earnings Call Transcript
2019-05-13 07:35:11 | Catalyst Pharmaceutical CPRX Reports Q1 Loss, Tops Revenue Estimates
2019-05-13 06:27:28 | Catalyst: 1Q Earnings Snapshot
2019-05-11 08:40:14 | The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs
2019-05-10 11:59:37 | Why Catalyst Pharmaceuticals Stock Is Jumping Today
2019-05-10 11:11:50 | Here’s Why Analysts Remain Confident on Catalyst CPRX Stock
2019-05-07 12:08:00 | Why Catalyst Pharmaceuticals Is Getting Crushed Today
2019-05-07 11:13:14 | Biopharma Eyes Worst Day in Years on Rival's FDA Nod
2019-05-07 11:10:26 | Catalyst Pharma Plummets On Competition For Pricey LEMS Drug
2019-05-06 19:23:00 | Catalyst Pharma stock plummets after FDA approves competitor's drug
2019-05-03 09:51:01 | What's in Store for Catalyst Pharma CPRX Q1 Earnings?
2019-04-17 09:30:01 | Catalyst CPRX Up 58.1% Since Last Earnings Report: Can It Continue?
2019-04-04 10:24:00 | Why Catalyst Pharmaceuticals, Inc. Soared in March
2019-03-31 09:00:00 | 3 Top Biotech Stocks to Buy Right Now
2019-03-26 14:31:50 | Why Wall Street Is Bullish on Catalyst Pharmaceuticals
2019-03-25 08:09:00 | 2 High-Growth Stocks I'd Buy Right Now
2019-03-19 18:16:19 | Edited Transcript of CPRX earnings conference call or presentation 19-Mar-19 12:30pm GMT
2019-03-19 17:23:00 | Why Catalyst Pharmaceuticals Stock Is Popping Today
2019-03-19 14:26:06 | Catalyst CPRX Reports Wider Q4 Loss, Focuses on Firdapse
2019-03-18 16:52:23 | Catalyst: 4Q Earnings Snapshot
2019-02-28 13:44:28 | U.S. Senator Sanders urges FDA to allow older versions of $375,000 drug
2019-02-28 08:03:00 | Catalyst Pharmaceuticals Announces Support of Rare Disease Day 2019
2019-02-21 14:28:05 | Catalyst Pharmaceuticals defends $375,000 drug price after Bernie Sanders rebuke
2019-02-21 09:00:00 | Catalyst Pharmaceuticals Responds to Letter from Senator Bernie Sanders
2019-02-11 14:58:05 | Catalyst Pharma sees net price of drug, once free, topping $300,000
2019-02-06 14:39:06 | Coral Gables company under fire for drug pricing says patient care is 'top priority'
2019-02-05 08:03:00 | Catalyst Pharmaceuticals to Present at the 21st Annual BIO CEO & Investor Conference
2019-02-04 10:34:04 | U.S. Senator Sanders asks why drug, once free, now costs $375k